Methods: A retrospective cohort study was perfomed to compare the characteristics and survival of relapsed patients with metachronous (m) mCRC. Patients were categorised into relapse at < 2yrs, 2-5 yrs and > 5yrs following their initial surgery. Univariate log-rank tests and and multivariate Cox regression was performed to determine whether time to relapse (TTR) and other factors were associated with overall survival (OS). Results: Of 750 mmCRC, 56% percent relapsed at < 2yrs, 32.4% at 2-5yrs, and 11.6% at > 5yrs. Patient characteristics are summarised in the table. Median OS, from the time of diagnosis of the recurrence, was 17 mths, 24.8 mths, and 26.5 mths respectively. Age (HR = 1.01, 95% CI=1.005-1.02, p=0.003) and liver resection (HR = 0.2, 95% CI=0.1-0.3, p < 0.001) were significant independent predictors of OS. TTR was also significantly associated with OS (HR = 0.75, 95 % CI = 0.60-0.93 and HR = 0.73, 95% CI = 0.53-1.01 respectively for 2-5 yrs and > 5 yrs versus < 2yrs, p < 0.05). There was no significant difference in survival between patients that relapsed at 5 yrs or later compared to those who relapsed between 2 and 5 yrs (HR = 0.98, 95% CI = 0.69-1.38, p = 0.90). Conclusions: TTR predicted shorter survival for mmCRC patients whose relapse occurred within 2 yrs. However, when comparing TTR 2-5 yrs and TTR > 5 yrs, there is no evidence that mmCRC patients with later relapse have a better prognosis.
|Publication status||Published - 2012|
|Event||2012 ASCO Gastrointestinal Cancers Symposium - Moscone West Building, San Francisco, United States|
Duration: 19 Jan 2012 → 21 Jan 2012
|Conference||2012 ASCO Gastrointestinal Cancers Symposium|
|Period||19/01/12 → 21/01/12|
- metastatic colorectal cancer (mCRC)
- curative surgery
- relapsed patients
Price, T. J., Beeke, C., Woodman, R., Karapetis, C., Kim, S., Maddern, G., Broadbridge, V., Hakendorf, P., & Padbury, R. (2012). Do metastatic colorectal cancer (mCRC) patients with late relapse after curative surgery have a better survival?. Poster session presented at 2012 ASCO Gastrointestinal Cancers Symposium, San Francisco, United States.